Abstract 6346: How case based education elevated clinical performance in metastatic breast cancer management: A study for TROP2 directed antibody drug conjugates

Abstract Background: The treatment landscape of metastatic breast cancer (mBC) has advanced with antibody-drug conjugates (ADCs), notably the TROP2-directed agents sacituzumab govitecan and datopotamab deruxtecan. These options have extended treatment potential for patients with HER2- mBC. However, rapid updates pose challenges for clinicians in adopting evidence-based, personalized strategies. Objective: To assess whether a digital, case-based, short-format CME activity could address knowledge and competence (K/C) gaps regarding the evidence-based use of TROP2-directed ADCs in HER2- mBC. Methods: A 15-minute, case-based, accredited online activity (“Opportunities to Personalize Care: Making the Case for TROP2-Directed ADCs in HR+, HER2- mBC”) launched March 28, 2025. Global academic and community oncologists completed pre-/post-assessments measuring K/C outcomes. A qualitative follow-up questionnaire, 4 weeks post-launch, evaluated practice changes and implementation behaviors. Results: As of June 3, 2025, 4,073 learners participated. Post-activity data showed a 20% mean improvement in K/C scores. Participants improved notably in identifying appropriate patients and applying ADCs in alignment with clinical evidence. The lowest baseline knowledge area—patient identification—showed marked gains, though further reinforcement may optimize impact in practice. Notably, 73% reported practice changes attributable to the activity. Post-education assessment revealed increased implementation of personalized and evidence-based treatment decision-making and adverse event management (Table 1 Table 1: Impact of Education on Practice Change Change in practice Initial analysis, %; n=33 4 week F/U after participation, %; N=55 Identify appropriate patients with HR+, HER2-negative mBC who are candidates for TROP2-directed ADCs 58 71 Recognize appropriate characteristics to select between ADCs for patients with HR+, HER2-negative mBC 64 85 Proactively implement best practices to manage AEs for patients with mBC on TROP2-directed ADCs 39 69 Apply guideline recommendations to select TROP2 directed ADCs for patients with HR+, HER2-negative metastatic breast cancer 48 56 ). Conclusion: This case-based CME activity effectively improved clinician K/C regarding TROP2-directed ADCs for HER2- mBC and supported sustained practice change. Personalized, digital education formats may accelerate integration of newly available and emerging therapies into oncology care. Citation Format: Meghan Coulehan, Serena Welch, Komal Jhaveri, Lavanya Anantharaman, Emily Kitterman, Aisha Suhail. How case based education elevated clinical performance in metastatic breast cancer management: A study for TROP2 directed antibody drug conjugates [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6346.